78544
葡萄糖四糖
≥99.0% (TLC)
别名:
Glcα1-6Glcα1-4Glcα1-4Glc
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C24H42O21
化学文摘社编号:
分子量:
666.58
NACRES:
NA.28
PubChem Substance ID:
UNSPSC Code:
12352201
MDL number:
Quality Level
assay
≥99.0% (TLC)
form
powder
color
white
suitability
corresponds for LC-MS
storage temp.
room temp
SMILES string
OC[C@H]1O[C@H](OC[C@H]2O[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3CO)O[C@H]4[C@H](O)[C@@H](O)C(O)O[C@@H]4CO)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O
InChI
1S/C24H42O21/c25-1-5-9(28)11(30)16(35)22(41-5)39-4-8-10(29)12(31)17(36)23(43-8)45-20-7(3-27)42-24(18(37)14(20)33)44-19-6(2-26)40-21(38)15(34)13(19)32/h5-38H,1-4H2/t5-,6-,7-,8-,9-,10-,11+,12+,13-,14-,15-,16-,17-,18-,19-,20-,21?,22+,23-,24-/m1/s1
InChI key
FPBCRLIOSBQLHS-QVTSYAGHSA-N
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
法规信息
涉药品监管产品
此项目有
Yoav H Messinger et al.
Genetics in medicine : official journal of the American College of Medical Genetics, 14(1), 135-142 (2012-01-13)
Infantile Pompe disease resulting from a deficiency of lysosomal acid α-glucosidase (GAA) requires enzyme replacement therapy (ERT) with recombinant human GAA (rhGAA). Cross-reactive immunologic material negative (CRIM-negative) Pompe patients develop high-titer antibody to the rhGAA and do poorly. We describe
Victoria Manwaring et al.
Journal of inherited metabolic disease, 35(2), 311-316 (2011-06-21)
A high performance liquid chromatography method, adapted from an established urinary sugars method, has been developed for the analysis of a tetraglucose oligomer (Glc(4)) in urine. Pompe disease results from defects in the activity of lysosomal acid α-glucosidase (GAA) with
Zoheb B Kazi et al.
Genetics in medicine : official journal of the American College of Medical Genetics, 21(4), 887-895 (2018-09-15)
To investigate immune tolerance induction with transient low-dose methotrexate (TLD-MTX) initiated with recombinant human acid α-glucosidase (rhGAA), in treatment-naïve cross-reactive immunologic material (CRIM)-positive infantile-onset Pompe disease (IOPD) patients. Newly diagnosed IOPD patients received subcutaneous or oral 0.4 mg/kg TLD-MTX for 3
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| 78544-1MG | 04061826054536 |